Data gathered: May 31
AI Stock Analysis - Assertio Therapeutics (ASRT)
Analysis generated February 17, 2024. Powered by Chat GPT.
Assertio Therapeutics is a pharmaceutical company known for its work in the development, commercialization, and sale of branded prescription medicines aimed at addressing significant needs in pain management and other neurological illnesses. The company's portfolio currently includes products that help manage conditions such as migraines, postherpetic neuralgia, and cancer-related pain.
Stock Alerts - Assertio Therapeutics (ASRT)
 |
Assertio Therapeutics | May 19 Price is up by 8% in the last 24h. |
|
Assertio Therapeutics | May 16 Price is up by 7.2% in the last 24h. |
|
Assertio Therapeutics | May 5 Price is down by -7.1% in the last 24h. |
|
Assertio Therapeutics | April 29 Price is up by 13.8% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Assertio Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,967 | Sign up | Sign up | Sign up |
| Twitter Followers | 60 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 36 | Sign up | Sign up | Sign up |
| Linkedin Employees | 55 | Sign up | Sign up | Sign up |
About Assertio Therapeutics
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system.
| Price | $0.66 |
| Target Price | Sign up |
| Volume | 110,620 |
| Market Cap | $66M |
| Year Range | $0.53 - $1.3 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Assertio Holdings, Inc. (ASRT) Q1 2025 Earnings Call TranscriptMay 12 - SeekingAlpha |
 |
Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees to Pay $3.6M to Resolve Allegations that It Violated the False Claims Act in Connection with Marketing its Fentanyl ProductMay 9 - Justice.gov |
Assertio Therapeutics to pay $3.6mln over alleged fentanyl product marketing violations, US DOJ saysMay 8 - Finnhub |
|
|
Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call TranscriptMarch 12 - SeekingAlpha |
Assertio : May 2025 OverviewMay 21 - Finnhub |
|
Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025May 19 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 26M | 7.8M | 19M | -13M | -13M | -0.040 |
| Q4 '24 | 32M | 12M | 21M | -10M | -3.3M | -0.030 |
| Q3 '24 | 29M | 7.6M | 22M | -2.9M | 4.6M | -0.030 |
| Q2 '24 | 31M | 8.9M | 22M | -3.7M | 3.9M | -0.040 |
| Q1 '24 | 32M | 17M | 16M | -4.5M | 2.1M | -0.050 |
Insider Transactions View All
| Mason Heather L filed to buy 287,650 shares at $0.8. November 19 '24 |
| O'Grady Brendan P. filed to buy 11,706 shares at $0.9. November 15 '24 |
| Vacirca Jeff L filed to buy 151,159 shares at $1.1. June 12 '24 |
| Mason Heather L filed to buy 212,650 shares at $1. June 6 '24 |
| Tyree James L filed to sell 188,251 shares at $1.1. March 15 '24 |
Similar companies
Read more about Assertio Therapeutics (ASRT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Assertio Therapeutics?
The Market Cap of Assertio Therapeutics is $66M.
What is the current stock price of Assertio Therapeutics?
Currently, the price of one share of Assertio Therapeutics stock is $0.66.
How can I analyze the ASRT stock price chart for investment decisions?
The ASRT stock price chart above provides a comprehensive visual representation of Assertio Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Assertio Therapeutics shares. Our platform offers an up-to-date ASRT stock price chart, along with technical data analysis and alternative data insights.
Does ASRT offer dividends to its shareholders?
As of our latest update, Assertio Therapeutics (ASRT) does not offer dividends to its shareholders. Investors interested in Assertio Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Assertio Therapeutics?
Some of the similar stocks of Assertio Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.